Presence and Type of Decompensation Affects Outcomes in Autoimmune Hepatitis Upon Treatment with Corticosteroids

Overview

Journal JGH Open

Specialty Gastroenterology

Date 2021 Jan 25

PMID 33490617

Citations 3

Authors

Sanchit Sharma

Samagra Agarwal

Kanav Kaushal

Abhinav Anand

Deepak Gunjan

Rajni Yadav

Anoop Saraya

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Decompensated cirrhosis in autoimmune hepatitis has poor prognosis. Besides liver transplant, treatment for this entity is undefined. We explored the outcomes of autoimmune hepatitis (AIH)-related decompensated cirrhosis with active disease on treatment with steroids.

Methods: In this retrospective analysis, clinical data, laboratory parameters, and prognostic scores, such as baseline model for end-stage liver disease (MELD) scores, were compared among patients of AIH with decompensated cirrhosis with mild/no ascites ( = 38), gross ascites ( = 24), and compensated cirrhosis ( = 32) when administered steroids. The primary outcome was transplant-free survival at 12 months. Biochemical remission rates and other adverse events were also assessed and compared between these groups.

Results: Steroids were initiated at lower doses (25 mg/day-mild/no ascites, 20 mg/day-gross ascites) in patients with decompensated cirrhosis and at 40 mg/day in those with compensated cirrhosis. Transplant-free survival was 25.4%, 74.6%, and 96.9% ( = 0.001), and biochemical remission occurred in 5.1%, 49.0%, and 64.1% ( = 0.001) at 12 months in patients with gross ascites, mild/no ascites, and compensated cirrhosis, respectively. Infections were seen more frequently in decompensated cirrhosis, while other adverse events were comparable. Among decompensated cirrhosis, those with mild/no ascites had better prognostic scores, fewer posttreatment infections, and more frequent biochemical remission than those with gross ascites, achieving rates comparable to compensated cirrhosis. On multivariate analysis, the MELD score (subdistributional hazards ratio [sHR]; 95% confidence interval: 1.153 [1.07-1.24]; = 0.001) and ascites (sHR: 2.556 [1.565-5.65]; = 0.020) predicted survival.

Conclusion: Type and severity of decompensation affect outcomes in patients with AIH-related cirrhosis. Those with mild/no ascites have comparable outcomes to those with compensated cirrhosis upon treatment with low-dose steroids.

Citing Articles

Immunosuppressive treatment in autoimmune decompensated cirrhosis, when to say enough: A retrospective analysis.

Barbero M, Burgos S, Roca I, Navarro L, Cairo F Medicine (Baltimore). 2025; 104(6):e41378.

PMID: 39928808 PMC: 11813046. DOI: 10.1097/MD.0000000000041378.

Outpatient management after hospitalisation for acute decompensation of cirrhosis: A practical guide.

Protopapas A, Tsankof A, Papagiouvanni I, Kaiafa G, Skoura L, Savopoulos C World J Hepatol. 2025; 16(12):1377-1394.

PMID: 39744202 PMC: 11686542. DOI: 10.4254/wjh.v16.i12.1377.

Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis.

Dalekos G, Papatheodoridis G, Koskinas J, Goulis I, Rigopoulou E, Tiniakos D Ann Gastroenterol. 2024; 37(6):623-654.

PMID: 39568707 PMC: 11574148. DOI: 10.20524/aog.2024.0924.

Autoimmmune hepatitis.

Beretta-Piccoli B, Mieli-Vergani G, Vergani D Cell Mol Immunol. 2021; 19(2):158-176.

PMID: 34580437 PMC: 8475398. DOI: 10.1038/s41423-021-00768-8.

References

Roberts S, Therneau T, Czaja A . Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996; 110(3):848-57. DOI: 10.1053/gast.1996.v110.pm8608895. View

Puustinen L, Barner-Rasmussen N, Pukkala E, Farkkila M . Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland. Dig Liver Dis. 2019; 51(9):1294-1299. DOI: 10.1016/j.dld.2019.01.015. View

Sarin S, Choudhury A, Sharma M, Maiwall R, Al Mahtab M, Rahman S . Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019; 13(4):353-390. PMC: 6728300. DOI: 10.1007/s12072-019-09946-3. View

. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018; 69(2):406-460. DOI: 10.1016/j.jhep.2018.03.024. View

Gupta R, Agarwal S, Jain M, Malhotra V, Sarin S . Autoimmune hepatitis in the Indian subcontinent: 7 years experience. J Gastroenterol Hepatol. 2001; 16(10):1144-8. DOI: 10.1046/j.1440-1746.2001.02602.x. View

Manns M, Czaja A, Gorham J, Krawitt E, Mieli-Vergani G, Vergani D . Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51(6):2193-213. DOI: 10.1002/hep.23584. View

Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, Hagh-Azali S, Rakhshani N, Tavangar S . Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci. 2005; 50(3):547-51. DOI: 10.1007/s10620-005-2472-5. View

van den Brand F, van der Veen K, de Boer Y, van Gerven N, Lissenberg-Witte B, Beuers U . Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2018; 17(5):940-947.e2. DOI: 10.1016/j.cgh.2018.09.046. View

Dufour J, DELELLIS R, KAPLAN M . Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997; 127(11):981-5. DOI: 10.7326/0003-4819-127-11-199712010-00006. View

10.

Pape S, Gevers T, Belias M, Mustafajev I, Vrolijk J, van Hoek B . Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2019; 17(10):2068-2075.e2. DOI: 10.1016/j.cgh.2018.12.035. View

11.

Werner M, Prytz H, Ohlsson B, Almer S, Bjornsson E, Bergquist A . Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008; 43(10):1232-40. DOI: 10.1080/00365520802130183. View

12.

Feld J, Dinh H, Arenovich T, Marcus V, Wanless I, Heathcote E . Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005; 42(1):53-62. DOI: 10.1002/hep.20732. View

13.

Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P . Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014; 60(6):1310-24. DOI: 10.1016/j.jhep.2014.01.024. View

14.

Liberal R, Grant C . Cirrhosis and autoimmune liver disease: Current understanding. World J Hepatol. 2016; 8(28):1157-1168. PMC: 5055585. DOI: 10.4254/wjh.v8.i28.1157. View

15.

ISHAK K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F . Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6):696-9. DOI: 10.1016/0168-8278(95)80226-6. View

16.

Mack C, Adams D, Assis D, Kerkar N, Manns M, Mayo M . Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2019; 72(2):671-722. DOI: 10.1002/hep.31065. View

17.

Gronbaek L, Vilstrup H, Jepsen P . Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2013; 60(3):612-7. DOI: 10.1016/j.jhep.2013.10.020. View

18.

Amarapurkar D, Dharod M, Amarapurkar A . Autoimmune hepatitis in India: single tertiary referral centre experience. Trop Gastroenterol. 2015; 36(1):36-45. DOI: 10.7869/tg.243. View

19.

. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 2015; 63(4):971-1004. DOI: 10.1016/j.jhep.2015.06.030. View

20.

Werner M, Wallerstedt S, Lindgren S, Almer S, Bjornsson E, Bergquist A . Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol. 2010; 45(4):457-67. DOI: 10.3109/00365520903555861. View